Rebound or Brick? Hemispherx Biopharma |
 |
 |
| By Vinny Cassano |
| Wednesday, 04 November 2009 16:31 |
 Shares of Hemispherx BioPharma, Inc (AMEX:HEB) rebounded slightly on Wednesday morning after sliding down to near the $1 mark on Tuesday- after it was announced that the company would spend the next two months responding to FDA queries regarding the company's New Drug Application for Ampligen.
Ampligen is up for approval as a treatment for Chronic Fatigue Syndrome.While Ampligen draws the news for Hemispherx at this time, the company also has already received FDA approval for Alferon, an injection that treats a category of sexually transmitted diseases. Both Ampligen and Alferon are also being evaluated in various early, middle and late stage trials to measure their effectiveness in treating various chronic diseases and viral disorders. The last time that I commented on HEB, the stock was trading for over two dollars and I thought that buying in for the first time at that point was a little too risky, in addition to my aversion to "stock chasing", but since the stock has dropped down to the one dollar level I believe there is potential for HEB to become a nice rebound play. I don't consider an Ampligen approval for CFS a slam dunk, but I do consider the approval as "necessary" to the company's survival in the sense that if they got a positive nod, HEB could then advance the rest of their clinical pipeline without having to raise significant funds. That would likely mean vicious dilution, in my opinion. It's hard to judge when an FDA decision will be rendered, but it's safe to say that if Hemispherx is still responding to inquiries, and will be doing so for the next two months, so a decision some time in middle of 2010 is not out of the question. The stock could be in for some continued volatility, so I'd buy a few shares while it is trading in the lower $1 range, then see how it plays out. With manipulation rampant in the sector these days, a dip to below one dollar is not out of the question, but neither is a speculative spike to near two dollars. As with all speculative stocks, it's a good idea to have already banked some profit and be fully on 'house money' by the time the FDA decision hits; if you've got some 'trading shares' on hand, then try to use them. Sometimes you'll miss out on a run if you've already sold some trading shares into a spike - but that's why you keep your 'base' shares in place, so you don't miss out completely. Conversely, if you've taken some profit during a runup, a subsequent drop in price won't hit you as hard. All just my opinion, of course. Do your own DD before buying. Disclosure: No Positions BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 12 hours ago
FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago
Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 1 day ago
Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago
Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago
Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 2 days ago
$CVM up 17% and technically looks like it may head higher.
about 2 days ago
$ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
Free Phone Trade Alerts
